# Title

 Food and Drugs. PART 26â€”MUTUAL RECOGNITION OF PHARMACEUTICAL GOOD MANUFACTURING PRACTICE REPORTS, MEDICAL DEVICE QUALITY SYSTEM AUDIT REPORTS, AND CERTAIN MEDICAL DEVICE PRODUCT EVALUATION REPORTS: UNITED STATES AND THE EUROPEAN COMMUNITY


# ID

 CFR-2018-title21-vol1.Pt. 26


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['within', 'prior to', 'before', 'after', 'at least']                                                                                                                                                                                                                                                                                                                                                                                         |
| Duration    | ['30.0 day', '2 month', '15.0 day', '6.0 month', '60.0 day', '45.0 day', '10.0 day', '90.0 day', '3.0 year', '1 day']                                                                                                                                                                                                                                                                                                                         |
| Condition   | ['until', 'unless', 'where', 'as soon as', 'subject to', 'provided that', 'when', 'if']                                                                                                                                                                                                                                                                                                                                                       |
| Entities    | ['United States', 'Equivalence', 'Participation', 'Such', 'Safeguard', 'Territorial', 'Nature', 'Either', 'Length', 'Role', 'Confidence', 'Entry', 'Rockville, MD', 'United States and Member States', 'Product', 'Exchange', 'Scope', 'Regulatory', 'Food', 'U.S. Federal', 'European Community', 'Human', 'Purpose', 'Suspension', 'Quality', 'Nonconfirmation', 'Switzerland', 'U.S.-type', 'U.S', 'America', 'Endorsement', 'Postmarket'] |
| Date        | ['1998-05-18', '2039-05-01']                                                                                                                                                                                                                                                                                                                                                                                                                  |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                           |
|:--------------|:----------------------------------------------------------------------------------------------------------------------------------|
| after         | of official good manufacturing practices (GMP's) inspection reports after a transitional period aimed at determination of the     |
| before        | and Member States of the European Community (EC) before products are marketed (hereafter referred to as &#8220;preapproval        |
| after         | European Community (EC) before products are marketed (here after referred to as &#8220;preapproval inspections&#8221;) as well as |
| after         | A 3-year transition period will start immediately  after  the effective date described in &#167;&#8201;26.80(a).                  |
| after         | authorities added to appendix B of this subpart after the effective date described in &#167;&#8201;26.80(a) will be               |
| within        | transmitted to the authority of the importing country within  60-calendar days of the request.                                    |
| within        | be needed, the inspection report will be transmitted within  90-calendar days of the request.                                     |
| within        | confirm its ability to carry out the inspection. within                                                                           |
| within        | (c) Reports of preapproval inspections will be sent  within 45-calendar days of the request that transmitted the                  |
| within        | If no unanimous consent is reached  within 30 days after such notification, the contested authority                               |
| after         | no unanimous consent is reached within 30 days after  such notification, the contested authority will be suspended.               |
| prior to      | normally endorse the inspection reports of that authority prior to suspension, unless the authority of the receiving party        |
| at least      | either party and, unless the cochairs otherwise agree, at least  once each year.                                                  |
| after         | start at the end of the transition period after the parties have developed the list of conformity                                 |
| within        | subpart shall be transmitted to the importing party within 60-calendar days of a request by the importing                         |
| within        | If the exporting party cannot perform an inspection  within a specified period of time, the importing party                       |
| after         | up during the transition period and maintained there after by which the parties will notify each other                            |
| within        | to control the use or sale of products within a party's jurisdiction and may take enforcement action                              |
| within        | to control the use or sale of products within a party's jurisdiction and may take enforcement action                              |
| within        | alleging its market access has been denied may, within 90 days of such consultation, invoke its right                             |
| within        | position regarding either its confirmation or its opposition. within                                                              |
| after         | B may be resubmitted to the other party. after                                                                                    |
| within        | not been resolved by the Joint Sectoral Committee within 10 days of the notice of contestation, the                               |
| within        | no decision is reached by the Joint Committee within 10 days of the referral to it, the                                           |
| prior to      | of conformity assessment procedures performed by that CAB prior to suspension, unless a regulatory authority of the party         |
| within        | environmental considerations or failure to satisfy other requirements within the scope of subpart B of this part;                 |
| at least      | party and shall be provided a period of at least 30 days from receipt to provide information in                                   |
| within        | position regarding either its confirmation or its opposition. within                                                              |
| prior to      | of conformity assessment procedures performed by that CAB prior to withdrawal, unless a regulatory authority of the party         |
| within        | environmental considerations or failure to satisfy other requirements within  the scope of subpart B of this part.                |
| at least      | related to the subject matter of this part at least  60 days before their entry into force.                                       |
| before        | matter of this part at least 60 days before  their entry into force.                                                              |
| within        | view to bringing such new or additional procedures within the scope of that agreement and the relevant                            |
| within        | for consumers; and otherwise with regard to risks within the scope of the applicable subpart A or                                 |
| within        | Not meet the legislative, regulatory, or administrative provisions within the scope of the applicable subpart A or                |
| within        | Not meet the legislative, regulatory, or administrative provisions within the scope of the applicable subpart A or                |
| within        | inform its counterpart authority and the other party within 15 days of taking such action, providing its                          |
| within        | loss of market access for the party's products within the scope of subpart A or B of                                              |
| within        | loss of market access for the party's products within the scope of subpart A or B of                                              |
| prior to      | performed by conformity assessment bodies under that agreement prior to termination, unless a regulatory authority in the party   |
| within        | environmental considerations or failure to satisfy other requirements within  the scope of the applicable sectoral annex.         |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.0 year   | A 3-year transition period will start immediately after the effective date described in &#167;&#8201;26.80(a).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 60.0 day   | Postapproval good manufacturing practice (GMP) inspection reports concerning products covered by this subpart will be transmitted to the authority of the importing country within 60-calendar days of the request.                                                                                                                                                                                                                                                                                                                                                                                             |
| 90.0 day   | Should a new inspection be needed, the inspection report will be transmitted within 90-calendar days of the request.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 15.0 day   | (b) Within 15-calendar days, the relevant authority will acknowledge receipt of the request and confirm its ability to carry out the inspection.                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 45.0 day   | (c) Reports of preapproval inspections will be sent within 45-calendar days of the request that transmitted the appropriate information and detailed the precise issues to be addressed during the inspection.                                                                                                                                                                                                                                                                                                                                                                                                  |
| 30.0 day   | If no unanimous consent is reached within 30 days after such notification, the contested authority will be suspended.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 3.0 year   | There will be a 3-year transition period immediately following the date described in &#167;&#8201;26.80(a).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 6.0 month  | (a) In the final 6 months of the transition period, the parties shall proceed to a joint assessment of the equivalence of the conformity assessment bodies (CAB's) that participated in the confidence building activities.                                                                                                                                                                                                                                                                                                                                                                                     |
| 60.0 day   | Quality system evaluation reports covered by &#167;&#8201;26.41 concerning products covered by this subpart shall be transmitted to the importing party within 60-calendar days of a request by the importing party.                                                                                                                                                                                                                                                                                                                                                                                            |
| 30.0 day   | Should a new inspection be requested, the time period shall be extended by an additional 30-calendar days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 90.0 day   | In the absence of a satisfactory outcome of such consultations, the party alleging its market access has been denied may, within 90 days of such consultation, invoke its right to terminate the &#8220;Agreement on Mutual Recognition Between the United States of America and the European Community,&#8221; from which this part is derived, in accordance with &#167;&#8201;26.80.                                                                                                                                                                                                                         |
| 60.0 day   | The following procedures shall apply with regard to the designation of conformity assessment bodies (CAB's) and the inclusion of such bodies in the list of CAB's in subpart B of this part:                                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (a) The designating authority identified in subpart B of this part shall designate CAB's in accordance with the procedures and criteria set forth in subpart B of this part;                                                                                                                                                                                                                                                                                                                                                                                                                      |
|            |               (b) A party proposing to add a CAB to the list of such bodies in subpart B of this part shall forward its proposal of one or more designated CAB's in writing to the other party with a view to a decision by the Joint Committee;                                                                                                                                                                                                                                                                                                                                                                |
|            |               (c) Within 60 days following receipt of the proposal, the other party shall indicate its position regarding either its confirmation or its opposition.                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 30.0 day   | Upon confirmation, the inclusion in subpart B of this part of the proposed CAB or CAB's shall take effect; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (d) In the event that the other party contests on the basis of documented evidence the technical competence or compliance of a proposed CAB, or indicates in writing that it requires an additional 30 days to more fully verify such evidence, such CAB shall not be included on the list of CAB's in subpart B of this part.                                                                                                                                                                                                                                                                    |
| 10.0 day   | If agreement to suspend is reached by the Joint Sectoral Committee or, if there is no Joint Sectoral Committee, by the Joint Committee, the CAB shall be suspended;                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|            |               (d) Where the Joint Sectoral Committee or Joint Committee decides that verification of technical competence or compliance is required, it shall normally be carried out in a timely manner by the party in whose territory the body in question is located, but may be carried out jointly by the parties in justified cases;                                                                                                                                                                                                                                                                     |
|            |               (e) If the matter has not been resolved by the Joint Sectoral Committee within 10 days of the notice of contestation, the matter shall be referred to the Joint Committee for a decision.                                                                                                                                                                                                                                                                                                                                                                                                         |
| 10.0 day   | If no decision is reached by the Joint Committee within 10 days of the referral to it, the CAB shall be suspended upon the request of the contesting party;                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 30.0 day   | The following procedures shall apply with regard to the withdrawal from subpart B of this part of a conformity assessment body (CAB):                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (a) A party proposing to withdraw a CAB listed in subpart B of this part shall forward its proposal in writing to the other party;                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (b) Such CAB shall be promptly notified by the other party and shall be provided a period of at least 30 days from receipt to provide information in order to refute or to correct the deficiencies which form the basis of the proposed withdrawal;                                                                                                                                                                                                                                                                                                                                              |
|            |               (c) Within 60 days following receipt of the proposal, the other party shall indicate its position regarding either its confirmation or its opposition.                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 60.0 day   | The following procedures shall apply with regard to the withdrawal from subpart B of this part of a conformity assessment body (CAB):                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (a) A party proposing to withdraw a CAB listed in subpart B of this part shall forward its proposal in writing to the other party;                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|            |               (b) Such CAB shall be promptly notified by the other party and shall be provided a period of at least 30 days from receipt to provide information in order to refute or to correct the deficiencies which form the basis of the proposed withdrawal;                                                                                                                                                                                                                                                                                                                                              |
|            |               (c) Within 60 days following receipt of the proposal, the other party shall indicate its position regarding either its confirmation or its opposition.                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 60.0 day   | (b) Each party shall notify the other party of legislative, regulatory, and administrative changes related to the subject matter of this part at least 60 days before their entry into force.                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 15.0 day   | If the regulatory authority takes such action, it shall inform its counterpart authority and the other party within 15 days of taking such action, providing its reasons.                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1 day      | (a) The &#8220;Agreement on Mutual Recognition Between the United States of America and the European Community,&#8221; from which this part is derived, including its sectoral annexes on telecommunication equipment, electromagnetic compatibility, electrical safety, recreational craft, pharmaceutical Good Manufacturing Practices (GMP) inspections, and medical devices shall enter into force on the first day of the second month following the date on which the parties have exchanged letters confirming the completion of their respective procedures for the entry into force of that agreement. |
| 2 month    | (a) The &#8220;Agreement on Mutual Recognition Between the United States of America and the European Community,&#8221; from which this part is derived, including its sectoral annexes on telecommunication equipment, electromagnetic compatibility, electrical safety, recreational craft, pharmaceutical Good Manufacturing Practices (GMP) inspections, and medical devices shall enter into force on the first day of the second month following the date on which the parties have exchanged letters confirming the completion of their respective procedures for the entry into force of that agreement. |
| 30.0 day   | Such annex shall enter into force 30 days following the date on which those parties have exchanged letters confirming the completion of their respective procedures for the entry into force of the sectoral annex.                                                                                                                                                                                                                                                                                                                                                                                             |
| 6.0 month  | (c) Either party to that agreement may terminate that agreement in its entirety or any individual sectoral annex thereof by giving the other party to that agreement 6-months notice in writing.                                                                                                                                                                                                                                                                                                                                                                                                                |
| 6.0 month  | Failing such consensus, that agreement shall terminate at the end of 6 months from the date of notice.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 3.0 year   | (d) In the case of subpart B of this part, the parties shall review the status of such subpart at the end of 3 years from the date described in &#167;&#8201;26.80(a).                                                                                                                                                                                                                                                                                                                                                                                                                                          |


## Condition

| Condition     | Context                                                                                                                         |
|:--------------|:--------------------------------------------------------------------------------------------------------------------------------|
| where         | of this part, the terms &#8220;party&#8221; or &#8220;parties,&#8221; where relevant to FDA's implementation of the MRA, should |
| as soon as    | will be conducted as described in this subpart, as soon as  practicable.                                                        |
| when          | (b) In addition,  when an authority is not listed as equivalent based                                                           |
| provided that | its territory and another authority listed as equivalent, provided that the authority of the Member State in which              |
| when          | (b) In addition,  when an authority is not listed as equivalent based                                                           |
| provided that | Directive 75/319/EEC (see appendix A of this subpart) provided that these controls have been carried out in the                 |
| where         | carry out an inspection of the production facility. where                                                                       |
| as soon as    | may have to take place will be made as soon as  possible.                                                                       |
| unless        | inspection reports of that authority prior to suspension, unless the authority of the receiving party decides otherwise         |
| until         | The suspension will remain in effect  until unanimous consent has been reached by the parties                                   |
| unless        | meet at the request of either party and, unless the cochairs otherwise agree, at least once each                                |
| subject to    | and other regulatory and enforcement problems for products subject to  this subpart.                                            |
| where         | this subpart shall apply to the exchange and, where appropriate, endorsement of the following types of reports                  |
| subject to    | (b) Additional products and procedures may be made  subject to  this subpart by agreement of the parties.                       |
| if            | in the respective territories of the parties, except if  the parties agree otherwise.                                           |
| if            | information, the importing party may request additional clar if ication from the CAB.                                           |
| subject to    | assessment bodies (CAB's) listed for this purpose will, subject to the specifications and limitations on the list, provide      |
| subject to    | (b) U.S. CAB's will,  subject to the specifications and limitations on the list, provide                                        |
| when          | by which the parties will notify each other when  there is an immediate danger to public health.                                |
| where         | assurance offered by the receiving party's own procedures. where                                                                |
| unless        | standards or technical regulations of the parties and, unless otherwise specified in subpart A or B of                          |
| unless        | in subparts A and B of this part, unless either party documents that the conditions provided in                                 |
| when          | Such contestation shall be exercised  when justified in an objective and reasoned manner in                                     |
| if            | is reached by the Joint Sectoral Committee or, if there is no Joint Sectoral Committee, by the                                  |
| where         | referred to the Joint Committee for a decision. where                                                                           |
| if            | is reached by the Joint Sectoral Committee or, if there is no Joint Sectoral Committee, by the                                  |
| unless        | procedures performed by that CAB prior to suspension, unless a regulatory authority of the party decides otherwise              |
| until         | and (g) The suspension shall remain in effect until agreement has been reached by the parties upon                              |
| unless        | procedures performed by that CAB prior to withdrawal, unless a regulatory authority of the party decides otherwise              |
| as soon as    | action, a party shall notify the other party as soon as  practicable.                                                           |
| when          | of that agreement and the relevant sectoral annex. when                                                                         |
| where         | Except  where there is written agreement between the parties, obligations                                                       |
| unless        | assessment bodies under that agreement prior to termination, unless a regulatory authority in the party decides otherwise       |


## Entities

| Entities                        | Context                                                                                                                                                            |
|:--------------------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food                            | Food  and Drugs.                                                                                                                                                   |
| United States                   | of the &#8220;Agreement on Mutual Recognition Between the United States of America and the European Community&#8221; (the MRA),                                    |
| America                         | on Mutual Recognition Between the United States of America and the European Community&#8221; (the MRA), signed at                                                  |
| United States                   | the text of the MRA concluded between the United States and the European Community (EC), or the rights                                                             |
| United States                   | the text of the MRA concluded between the United States and the European Community (EC), or the rights                                                             |
| United States                   | Whereas the parties to the MRA are the  United States and EC, this part is relevant only to                                                                        |
| U.S. Federal                    | address implementation of the MRA by other concerned U.S. Federal  agencies.                                                                                       |
| Equivalence                     | Equivalence does not require that the respective regulatory systems                                                                                                |
| United States                   | [The  United States has clarified its interpretation that under the MRA,                                                                                           |
| U.S                             | this section has to be understood as the U.S . definition and paragraph (c)(2) as the EC                                                                           |
| Purpose                         | Purpose .                                                                                                                                                          |
| Scope                           | Scope .                                                                                                                                                            |
| United States and Member States | apply to pharmaceutical inspections carried out in the United States and Member States of the European Community (EC) before products are                          |
| Product                         | Product  coverage.                                                                                                                                                 |
| United States                   | active pharmaceutical ingredients (as referred to in the United States ), only to the extent they are regulated                                                    |
| Human                           | Human plasma derivatives (such as immunoglobulins and albumin), investigational                                                                                    |
| Length                          | Length  of transition period.                                                                                                                                      |
| Equivalence                     | Equivalence  assessment.                                                                                                                                           |
| Equivalence                     | (d)  Equivalence assessment for authorities added to appendix B of                                                                                                 |
| Participation                   | Participation  in the equivalence assessment and determination.                                                                                                    |
| Equivalence                     | Equivalence  determination.                                                                                                                                        |
| Regulatory                      | Regulatory  authorities not listed as currently equivalent.                                                                                                        |
| United States                   | these controls have been carried out in the United States and that each batch/lot is accompanied by a                                                              |
| Nature                          | Nature  of recognition of inspection reports.                                                                                                                      |
| Suspension                      | Suspension .                                                                                                                                                       |
| Role                            | Role  and composition of the Joint Sectoral Committee.                                                                                                             |
| United States                   | the Food and Drug Administration (FDA) for the United States and a representative of the European Community (EC)                                                   |
| Safeguard                       | Safeguard  clause.                                                                                                                                                 |
| Purpose                         | Purpose .                                                                                                                                                          |
| European Community              | subpart as Food and Drug Administration (FDA) and European Community  (EC) policies evolve over time.                                                              |
| Scope                           | Scope .                                                                                                                                                            |
| U.S                             | (CAB's) assessed to be equivalent: (1) Under the U.S . system, surveillance/postmarket and initial/preapproval inspection reports; (2)                             |
| U.S                             | (CAB's) assessed to be equivalent: (1) Under the U.S . system, surveillance/postmarket and initial/preapproval inspection reports; (2)                             |
| U.S                             | of conducting product and quality systems evaluations against U.S . regulatory requirements in a manner equivalent to                                              |
| United States                   | those conducted by FDA; and CAB's in the United States are capable of conducting product and quality systems                                                       |
| Product                         | Product  coverage.                                                                                                                                                 |
| U.S.-type                       | U.S.-type surveillance/postmarket and initial/preapproval inspection reports and European Community                                                                |
| European Community              | U.S.-type surveillance/postmarket and initial/preapproval inspection reports and  European Community (EC)-type quality system evaluation reports will be exchanged |
| U.S                             | U.S .-type surveillance/postmarket and initial/preapproval inspection reports and European                                                                         |
| U.S.-type                       | U.S.-type premarket (510(k)) product evaluation reports and EC-type-testing reports                                                                                |
| U.S                             | U.S .-type premarket (510(k)) product evaluation reports and EC-type-testing                                                                                       |
| Postmarket                      | Postmarket vigilance reports will be exchanged with regard to                                                                                                      |
| U.S                             | with regard to all products regulated under both U.S . and EC law as medical devices.                                                                              |
| Regulatory                      | Regulatory  authorities.                                                                                                                                           |
| Regulatory                      | Regulatory authorities will be specified in appendix C of                                                                                                          |
| Length                          | Length  and purpose of transition period.                                                                                                                          |
| Nonconfirmation                 | Nonconfirmation would have to be justified based on documented                                                                                                     |
| Confidence                      | Confidence  building activities.                                                                                                                                   |
| Equivalence                     | Equivalence  assessment.                                                                                                                                           |
| Exchange                        | Exchange  and endorsement of quality system evaluation reports.                                                                                                    |
| U.S                             | (b) Listed  U.S . CAB's will provide to the EC Notified                                                                                                            |
| Exchange                        | Exchange  and endorsement of product evaluation reports.                                                                                                           |
| U.S                             | FDA 510(k) premarket notification assessment reports prepared to U.S . medical device requirements.                                                                |
| U.S                             | (b)  U.S . CAB's will, subject to the specifications and                                                                                                           |
| Endorsement                     | Endorsement  remains the responsibility of the importing party.                                                                                                    |
| Quality                         | Quality system evaluation reports covered by &#167;&#8201;26.41 concerning products                                                                                |
| Role                            | Role  and composition of the Joint Sectoral Committee.                                                                                                             |
| United States                   | the Food and Drug Administration (FDA) for the United States and a representative of the European Community (EC)                                                   |
| Such                            | Such participation involves developing and reviewing documents developed by                                                                                        |
| Switzerland                     | de Varemb&#233;, Case postale 56, CH-1211 Gen&#232;ve 20, Switzerland , or on the Internet at http://www.iso.ch or                                                 |
| Rockville, MD                   | 11B-40,  Rockville, MD 20857, or at the National Archives and Records                                                                                              |
| Purpose                         | Purpose  of this part.                                                                                                                                             |
| United States                   | terminate the &#8220;Agreement on Mutual Recognition Between the United States of America and the European Community,&#8221; from which                            |
| America                         | on Mutual Recognition Between the United States of America and the European Community,&#8221; from which this part                                                 |
| United States                   | (a) The  United States shall, as specified in subparts A and B                                                                                                     |
| United States                   | (a) The  United States shall, as specified in subparts A and B                                                                                                     |
| Such                            | Such contestation shall be exercised when justified in an                                                                                                          |
| United States                   | A Joint Committee consisting of representatives of the United States  and the European Community (EC) will be established.                                         |
| United States                   | of the &#8220;Agreement on Mutual Recognition Between the United States of America and the European Community,&#8221; from which                                   |
| America                         | on Mutual Recognition Between the United States of America and the European Community,&#8221; from which this part                                                 |
| United States                   | (c) The  United States and the EC shall each have one vote                                                                                                         |
| Either                          | Either party may suspend its obligations under subpart A                                                                                                           |
| Territorial                     | Territorial  application.                                                                                                                                          |
| United States                   | the other hand, to the territory of the United States .                                                                                                            |
| Entry                           | Entry  into force, amendment, and termination.                                                                                                                     |
| United States                   | (a) The &#8220;Agreement on Mutual Recognition Between the  United States of America and the European Community,&#8221; from which                                 |
| America                         | on Mutual Recognition Between the United States of America and the European Community,&#8221; from which this part                                                 |
| United States                   | of the &#8220;Agreement on Mutual Recognition Between the United States of America and the European Community,&#8221; from which                                   |
| America                         | on Mutual Recognition Between the United States of America and the European Community,&#8221; from which this part                                                 |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                            |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1998-05-18 | This part substantially reflects relevant provisions of the framework agreement and its sectoral annexes on pharmaceutical good manufacturing practices (GMP's) and medical devices of the &#8220;Agreement on Mutual Recognition Between the United States of America and the European Community&#8221; (the MRA), signed at London May 18, 1998. |
| 2039-05-01 | (b) Once a designating authority considers that such CAB's, having undergone the procedures of &#167;&#167;&#8201;26.36, 26.37, and 26.39, may be determined to be equivalent, it will then designate those bodies on an annual basis.                                                                                                             |


